Sanggenol L induces ferroptosis in non-small cell lung cancer cells via regulating the miR-26a-1-3p/MDM2/p53 signaling pathway

被引:7
作者
Fu, Rong [1 ]
You, Yujie [1 ]
Wang, Yuqing [2 ]
Wang, Jue [3 ]
Lu, Yu [1 ]
Gao, Rui [1 ]
Pang, Min [4 ]
Yang, Peng [2 ]
Wang, Hailong [1 ]
机构
[1] Shanxi Med Univ, Sch Basic Med Sci, Taiyuan 030001, Peoples R China
[2] Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn Natl Minist Educ, Taiyuan 030006, Peoples R China
[3] Shanxi Med Univ, Hosp 1, Dept Prosthodont, Taiyuan 030001, Shanxi, Peoples R China
[4] Shanxi Med Univ, Hosp 1, Dept Pulm & Crit Care Med, Shanxi Prov Key Lab Resp Dis, Taiyuan, Peoples R China
基金
中国国家自然科学基金;
关键词
Sanggenol L; Ferroptosis; NSCLC; miR-26a-1-3p; MDM2;
D O I
10.1016/j.bcp.2024.116345
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ferroptosis is a regulated cell death marked by iron-dependent lipid peroxidation. Tumor cells that survive by evading chemotherapy-induced apoptosis are vulnerable to ferroptosis. Therefore, it is particularly urgent to explore active ingredients that can selectively induce ferroptosis in cancer cells. Here, we revealed that sanggenol L, the active agent of Morus Bark, predisposed non-small cell lung cancer (NSCLC) cells to ferroptosis, evidenced by reactive oxygen species (ROS) accumulation, glutathione depletion, mitochondrial shrinkage, and lipid peroxidation. Furthermore, the ferroptosis-related miRNA array showed that sanggenol L treatment upregulated the level of miR-26a-1-3p, which directly targeted the E3 ubiquitin ligase MDM2. In addition, silencing MDM2 by miR-26a-1-3p resulted in a notable increase in p53 protein levels and decrease of its downstream target SLC7A11, ultimately triggered ferroptosis. The subcutaneous xenograft model and patient-derived tumor xenograft (PDX) model of NSCLC further confirmed the anti-tumor efficacy and safety of sanggenol L in vivo. Collectively, our data suggest that miR-26a-1-3p/MDM2/p53/SLC7A11 signaling axis plays a key role in sanggenol L-induced ferroptosis, which implies that sanggenol L can serves as an anticancer therapeutic arsenal for NSCLC.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] p53 status and prognosis in stage I-IIIa non-small cell lung cancer
    Ohno, A
    Hirashima, T
    Kubo, A
    Masuda, N
    Takada, M
    Fujiwara, H
    Yasumitsu, T
    Kikui, M
    Fukuoka, M
    Nakagawa, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1997, 10 (03) : 521 - 528
  • [42] BRG1 and p53 Expression in Resected Stage I - III Non-Small Cell Lung Cancer
    Elegbede, A.
    Koebel, M.
    D'Silva, A.
    Dean, M.
    Enwere, E.
    Tudor, R.
    Gibson, A.
    Li, H.
    Otsuka, S.
    Bebb, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2124 - S2124
  • [43] TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value
    Deben, Christophe
    Deschoolmeester, Vanessa
    Lardon, Filip
    Rolfo, Christian
    Pauwels, Patrick
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 99 : 63 - 73
  • [44] Penicilazaphilone C triggers ferroptosis in triple-negative breast cancer cells via the MDM2/p53/SLC7 A11/GPX4 pathway
    Hua-Tao Liang
    Feng-Ying Huang
    Wei-Jing Xie
    Ming-Hui Chen
    Ri-Hong Wu
    Shu-Zhen Dai
    Wen-Tian Xu
    Wu-Ping Zheng
    Guang-Hong Tan
    Discover Oncology, 16 (1)
  • [45] Effect of lncRNA00511 on Non-Small Cell Lung Cancer by Regulating miR-29b-3p
    Li, Chunlin
    Li, Zhenyu
    Yi, Hua
    Liu, Zhidong
    JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2022, 12 (08) : 1490 - 1496
  • [46] Isoharringtonine Induces Apoptosis of Non-Small Cell Lung Cancer Cells in Tumorspheroids via the Intrinsic Pathway
    Lee, Ji Hae
    Park, So-Young
    Hwang, Wonbin
    Sung, Jee Young
    Cho, Myoung-Lae
    Shim, Jaegal
    Kim, Yong-Nyun
    Yoon, Kyungsil
    BIOMOLECULES, 2020, 10 (11) : 1 - 18
  • [47] The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer
    Gregorc, V
    Darwish, S
    Ludovini, V
    Pistola, L
    De Angelis, V
    Mihaylova, Z
    Bellezza, G
    Sidoni, A
    Cavaliere, A
    Bucciarelli, E
    Massaro, G
    Tonato, M
    LUNG CANCER, 2003, 42 (03) : 275 - 281
  • [48] Ze-Qi decoction inhibits non-small cell lung cancer growth and metastasis by modulating the PI3K/Akt/p53 signaling pathway
    Zhang, Jingtao
    Zhuang, Zifan
    Guo, Minghao
    Wu, Kai
    Yang, Qingfeng
    Min, Xin
    Cui, Wenqiang
    Xu, Fei
    JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE, 2023, 13 (05): : 417 - 429
  • [49] β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling
    Wang, Li-huai
    Sun, Yin-hui
    Liu, Hua
    Yang, Xiao
    Wen, Zhi
    Tian, Xue-fei
    CHEMICAL BIOLOGY & DRUG DESIGN, 2024, 103 (03)
  • [50] LncRNA NCK1-AS1 promotes non-small cell lung cancer progression via regulating miR-512-5p/p21 axis
    Luo, Xiping
    Zhou, Juan
    Quan, Lingli
    Liang, Yanchao
    Chen, Fangwei
    Liu, Shuangbo
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)